BFH772
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407229

CAS#: 890128-81-1

Description: BFH772, a structure analogue of BAW2881, is a potent and selective VEGF inhibitor. BFH772 is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. BFH772 inhibits the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases, with IC50 values ranging between 30 and 160 nM.


Price and Availability

Size
Price

100mg
USD 950
1g
USD 3250
Size
Price

200mg
USD 1650
2g
USD 4950
Size
Price

500mg
USD 2150
5g
Ask price

BFH772, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 407229
Name: BFH772
CAS#: 890128-81-1
Chemical Formula: C23H16F3N3O3
Exact Mass: 439.1144
Molecular Weight: 439.39
Elemental Analysis: 62.87; H, 3.67; F, 12.97; N, 9.56; O, 10.92


Synonym: BFH-772; BFH 772; BFH772.

IUPAC/Chemical Name: 6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide

InChi Key: JNLSTLQFDDAULK-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)

SMILES Code: O=C(C1=C2C=CC(OC3=NC=NC(CO)=C3)=CC2=CC=C1)NC4=CC=CC(C(F)(F)F)=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
Guido Bold, Christian Schnell, Pascal Furet, Paul McSheehy, Josef Brüggen, Jürgen Mestan, Paul W. Manley, Peter Drückes, Marion Burglin, Ursula Dürler, Jacqueline Loretan, Robert Reuter, Markus Wartmann, Andreas Theuer, Beatrice Bauer-Probst, Georg Martiny-Baron, Peter Allegrini, Arnaud Goepfert, Jeanette Wood, and Amanda Littlewood-Evans
Publication Date (Web): December 2, 2015 (Article)
DOI: 10.1021/acs.jmedchem.5b01582